Skip to main content
. Author manuscript; available in PMC: 2017 Jun 20.
Published in final edited form as: Clin Rev Allergy Immunol. 2013 Apr;44(2):114–120. doi: 10.1007/s12016-011-8296-5

Figure 1.

Figure 1

Autoimmune diseases initiated with the IL-23/TH17 response secrete high levels of IL17A and IL-17F. IL-17A and F initiates granulocyte infiltration to the site of inflammation as well as orchestrates germinal center formation and B-cell maturation in lymphoid tissues. Endogenously expressed or therapeutically administered IFN-β could exacerbate TH17 diseases by directly stimulating granulocytes to release tissue destructive proteases and cytokines or by elevating BAFF to enhance the production of auto-reactive antibodies and memory B-cells.